Skip to main content
Erschienen in: Medical Oncology 6/2014

01.06.2014 | Original Paper

Prognostic factors that govern localized synovial sarcoma: a single institution retrospective study on 51 patients

verfasst von: Sameer Yaser, Samer Salah, Marwa Al-Shatti, Areej Abu-Sheikha, Ahmad Shehadeh, Iyad Sultan, Ahmad Salem, Maher Sughayer, Shaymaa Al-Loh, Abdelatif Al-Mousa

Erschienen in: Medical Oncology | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Synovial sarcoma is a rare type of sarcoma with poor prognosis. Data on relevant prognostic factors are inconsistent. The objective of this study was to determine the independent prognostic factors that govern local recurrence, distant metastasis and overall survival. A retrospective analysis of 51 patients treated for localized synovial sarcoma at a single institution by a multidisciplinary/multimodality approach over a period of 12 years. Patients, tumor and treatment characteristics were collected including age, sex, tumor site, location, depth, size, status of margins, histology subtype and involvement of bone or lymph nodes. Type of surgery, adjuvant chemotherapy and radiotherapy were also examined. The endpoints analyzed were local recurrence-free survival (LRFS), metastasis-free survival (MFS) and overall survival (OS). Median age of patients was 26 years (range 3–64 years) with 73 % above the age of 20 year. All patients received surgery, 57 % received adjuvant radiotherapy and 45 % adjuvant chemotherapy. The median survival was 111 months, and 5-year OS was 73 %. Deep seatedness of the tumor was linked to OS as the only independent risk factor. Twelve patients had local recurrence, and the 5-year LRFS was 61 %. Multivariate analysis determined negative margins and adjuvant radiotherapy as independent predicting factors for LRFS. Five-year MFS was 48 %; multivariate analysis identified monophasic subtype and site other than lower extremity as the only independent factors associated with inferior MFS. The most important factors that govern LRFS and MFS are negative margins and adjuvant radiotherapy for LRFS and tumor histology and site for MFS, while deep seatedness of the tumor is the sole independent factor that governs OS.
Literatur
1.
Zurück zum Zitat Brennan MF SS, Maki RG, et al. Sarcomas of the soft tissues and bone. DeVita VT, Hellmann S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 2005;35:1584. Brennan MF SS, Maki RG, et al. Sarcomas of the soft tissues and bone. DeVita VT, Hellmann S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 2005;35:1584.
2.
Zurück zum Zitat Levi F, La Vecchia C, Randimbison L, Te VC. Descriptive epidemiology of soft tissue sarcomas in Vaud, Switzerland. Eur J Cancer. 1999;35(12):1711–6.PubMedCrossRef Levi F, La Vecchia C, Randimbison L, Te VC. Descriptive epidemiology of soft tissue sarcomas in Vaud, Switzerland. Eur J Cancer. 1999;35(12):1711–6.PubMedCrossRef
3.
Zurück zum Zitat Ross JA, Severson RK, Davis S, Brooks JJ. Trends in the incidence of soft tissue sarcomas in the United States from 1973 through 1987. Cancer. 1993;72(2):486–90.PubMedCrossRef Ross JA, Severson RK, Davis S, Brooks JJ. Trends in the incidence of soft tissue sarcomas in the United States from 1973 through 1987. Cancer. 1993;72(2):486–90.PubMedCrossRef
4.
Zurück zum Zitat Rydholm A, Berg NO, Gullberg B, Thorngren KG, Persson BM. Epidemiology of soft-tissue sarcoma in the locomotor system. A retrospective population-based study of the inter-relationships between clinical and morphologic variables. Acta Pathol Microbiol Immunol Scand A Pathol. 1984;92(5):363–74. Rydholm A, Berg NO, Gullberg B, Thorngren KG, Persson BM. Epidemiology of soft-tissue sarcoma in the locomotor system. A retrospective population-based study of the inter-relationships between clinical and morphologic variables. Acta Pathol Microbiol Immunol Scand A Pathol. 1984;92(5):363–74.
5.
Zurück zum Zitat Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: an analysis of 26,758 cases. Int J Cancer. 2006;119(12):2922–30. doi:10.1002/ijc.22239.PubMedCrossRef Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: an analysis of 26,758 cases. Int J Cancer. 2006;119(12):2922–30. doi:10.​1002/​ijc.​22239.PubMedCrossRef
6.
Zurück zum Zitat Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, et al. Impact of SYT–SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 2002;62(1):135–40.PubMed Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, et al. Impact of SYT–SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 2002;62(1):135–40.PubMed
9.
Zurück zum Zitat Rubin BP, Fletcher CD, Inwards C, Montag AG, Peabody T, Qualman SJ, et al. Protocol for the examination of specimens from patients with soft tissue tumors of intermediate malignant potential, malignant soft tissue tumors, and benign/locally aggressive and malignant bone tumors. Arch Pathol Lab Med. 2006;130(11):1616–29. doi:10.1043/1543-2165(2006)130[1616:PFTEOS]2.0.CO;2.PubMed Rubin BP, Fletcher CD, Inwards C, Montag AG, Peabody T, Qualman SJ, et al. Protocol for the examination of specimens from patients with soft tissue tumors of intermediate malignant potential, malignant soft tissue tumors, and benign/locally aggressive and malignant bone tumors. Arch Pathol Lab Med. 2006;130(11):1616–29. doi:10.​1043/​1543-2165(2006)130[1616:​PFTEOS]2.​0.​CO;2.PubMed
10.
Zurück zum Zitat Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997;15(1):350–62.PubMed Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997;15(1):350–62.PubMed
11.
Zurück zum Zitat Wright PH, Sim FH, Soule EH, Taylor WF. Synovial sarcoma. J Bone Joint Surg Am. 1982;64(1):112–22.PubMed Wright PH, Sim FH, Soule EH, Taylor WF. Synovial sarcoma. J Bone Joint Surg Am. 1982;64(1):112–22.PubMed
12.
Zurück zum Zitat Pack GT, Ariel IM. Synovial sarcoma (malignant synovioma); a report of 60 cases. Surgery. 1950;28(6):1047–84.PubMed Pack GT, Ariel IM. Synovial sarcoma (malignant synovioma); a report of 60 cases. Surgery. 1950;28(6):1047–84.PubMed
13.
Zurück zum Zitat el-Naggar AK, Ayala AG, Abdul-Karim FW, McLemore D, Ballance WW, Garnsey L, et al. Synovial sarcoma. A DNA flow cytometric study. Cancer. 1990;65(10):2295–300.PubMedCrossRef el-Naggar AK, Ayala AG, Abdul-Karim FW, McLemore D, Ballance WW, Garnsey L, et al. Synovial sarcoma. A DNA flow cytometric study. Cancer. 1990;65(10):2295–300.PubMedCrossRef
14.
Zurück zum Zitat Oda Y, Hashimoto H, Tsuneyoshi M, Takeshita S. Survival in synovial sarcoma. A multivariate study of prognostic factors with special emphasis on the comparison between early death and long-term survival. Am J Surg Pathol. 1993;17(1):35–44.PubMedCrossRef Oda Y, Hashimoto H, Tsuneyoshi M, Takeshita S. Survival in synovial sarcoma. A multivariate study of prognostic factors with special emphasis on the comparison between early death and long-term survival. Am J Surg Pathol. 1993;17(1):35–44.PubMedCrossRef
15.
Zurück zum Zitat Ferrari A, Gronchi A, Casanova M, Meazza C, Gandola L, Collini P, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer. 2004;101(3):627–34. doi:10.1002/cncr.20386.PubMedCrossRef Ferrari A, Gronchi A, Casanova M, Meazza C, Gandola L, Collini P, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer. 2004;101(3):627–34. doi:10.​1002/​cncr.​20386.PubMedCrossRef
16.
Zurück zum Zitat Bergh P, Meis-Kindblom JM, Gherlinzoni F, Berlin O, Bacchini P, Bertoni F, et al. Synovial sarcoma: identification of low and high risk groups. Cancer. 1999;85(12):2596–607.PubMedCrossRef Bergh P, Meis-Kindblom JM, Gherlinzoni F, Berlin O, Bacchini P, Bertoni F, et al. Synovial sarcoma: identification of low and high risk groups. Cancer. 1999;85(12):2596–607.PubMedCrossRef
17.
Zurück zum Zitat Lewis JJ, Antonescu CR, Leung DH, Blumberg D, Healey JH, Woodruff JM, et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol. 2000;18(10):2087–94.PubMed Lewis JJ, Antonescu CR, Leung DH, Blumberg D, Healey JH, Woodruff JM, et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol. 2000;18(10):2087–94.PubMed
18.
Zurück zum Zitat Spillane AJ, A’Hern R, Judson IR, Fisher C, Thomas JM. Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol. 2000;18(22):3794–803.PubMed Spillane AJ, A’Hern R, Judson IR, Fisher C, Thomas JM. Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol. 2000;18(22):3794–803.PubMed
19.
Zurück zum Zitat Cagle LA, Mirra JM, Storm FK, Roe DJ, Eilber FR. Histologic features relating to prognosis in synovial sarcoma. Cancer. 1987;59(10):1810–4.PubMedCrossRef Cagle LA, Mirra JM, Storm FK, Roe DJ, Eilber FR. Histologic features relating to prognosis in synovial sarcoma. Cancer. 1987;59(10):1810–4.PubMedCrossRef
20.
Zurück zum Zitat Trassard M, Le Doussal V, Hacene K, Terrier P, Ranchere D, Guillou L, et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol. 2001;19(2):525–34.PubMed Trassard M, Le Doussal V, Hacene K, Terrier P, Ranchere D, Guillou L, et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol. 2001;19(2):525–34.PubMed
21.
Zurück zum Zitat Hajdu SI, Shiu MH, Fortner JG. Tendosynovial sarcoma: a clinicopathological study of 136 cases. Cancer. 1977;39(3):1201–17.PubMedCrossRef Hajdu SI, Shiu MH, Fortner JG. Tendosynovial sarcoma: a clinicopathological study of 136 cases. Cancer. 1977;39(3):1201–17.PubMedCrossRef
23.
Zurück zum Zitat Schmidt D, Thum P, Harms D, Treuner J. Synovial sarcoma in children and adolescents. A report from the Kiel Pediatric Tumor Registry. Cancer. 1991;67(6):1667–72.PubMedCrossRef Schmidt D, Thum P, Harms D, Treuner J. Synovial sarcoma in children and adolescents. A report from the Kiel Pediatric Tumor Registry. Cancer. 1991;67(6):1667–72.PubMedCrossRef
24.
Zurück zum Zitat Fong Y, Coit DG, Woodruff JM, Brennan MF. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg. 1993;217(1):72–7.PubMedCentralPubMedCrossRef Fong Y, Coit DG, Woodruff JM, Brennan MF. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg. 1993;217(1):72–7.PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Cadman NL, Soule EH, Kelly PJ. Synovial sarcoma; an analysis of 34 tumors. Cancer. 1965;18:613–27.PubMedCrossRef Cadman NL, Soule EH, Kelly PJ. Synovial sarcoma; an analysis of 34 tumors. Cancer. 1965;18:613–27.PubMedCrossRef
26.
Zurück zum Zitat Oda Y, Hashimoto H, Takeshita S, Tsuneyoshi M. The prognostic value of immunohistochemical staining for proliferating cell nuclear antigen in synovial sarcoma. Cancer. 1993;72(2):478–85.PubMedCrossRef Oda Y, Hashimoto H, Takeshita S, Tsuneyoshi M. The prognostic value of immunohistochemical staining for proliferating cell nuclear antigen in synovial sarcoma. Cancer. 1993;72(2):478–85.PubMedCrossRef
27.
Zurück zum Zitat Roth JA, Enzinger FM, Tannenbaum M. Synovial sarcoma of the neck: a followup study of 24 cases. Cancer. 1975;35(4):1243–53.PubMedCrossRef Roth JA, Enzinger FM, Tannenbaum M. Synovial sarcoma of the neck: a followup study of 24 cases. Cancer. 1975;35(4):1243–53.PubMedCrossRef
28.
Zurück zum Zitat Singer S, Baldini EH, Demetri GD, Fletcher JA, Corson JM. Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival. J Clin Oncol. 1996;14(4):1201–8.PubMed Singer S, Baldini EH, Demetri GD, Fletcher JA, Corson JM. Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival. J Clin Oncol. 1996;14(4):1201–8.PubMed
29.
Zurück zum Zitat Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14(5):1679–89.PubMed Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14(5):1679–89.PubMed
30.
Zurück zum Zitat Mandard AM, Petiot JF, Marnay J, Mandard JC, Chasle J, de Ranieri E, et al. Prognostic factors in soft tissue sarcomas. A multivariate analysis of 109 cases. Cancer. 1989;63(7):1437–51.PubMedCrossRef Mandard AM, Petiot JF, Marnay J, Mandard JC, Chasle J, de Ranieri E, et al. Prognostic factors in soft tissue sarcomas. A multivariate analysis of 109 cases. Cancer. 1989;63(7):1437–51.PubMedCrossRef
32.
Zurück zum Zitat Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993;11(7):1269–75.PubMed Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993;11(7):1269–75.PubMed
33.
Zurück zum Zitat Bramwell V, Rouesse J, Steward W, Santoro A, Schraffordt-Koops H, Buesa J, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma–reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1994;12(6):1137–49.PubMed Bramwell V, Rouesse J, Steward W, Santoro A, Schraffordt-Koops H, Buesa J, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma–reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1994;12(6):1137–49.PubMed
34.
Zurück zum Zitat Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993;11(7):1276–85.PubMed Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993;11(7):1276–85.PubMed
35.
Zurück zum Zitat Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19(5):1238–47.PubMed Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19(5):1238–47.PubMed
36.
Zurück zum Zitat Gronchi A, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol. 2012;30(8):850–6. doi:10.1200/JCO.2011.37.7218.PubMedCrossRef Gronchi A, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol. 2012;30(8):850–6. doi:10.​1200/​JCO.​2011.​37.​7218.PubMedCrossRef
37.
Zurück zum Zitat Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Sarcoma Meta-analysis Collaboration (SMAC). The Cochrane database of systematic reviews. 2000(2):CD001419. doi:10.1002/14651858.CD001419. Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Sarcoma Meta-analysis Collaboration (SMAC). The Cochrane database of systematic reviews. 2000(2):CD001419. doi:10.​1002/​14651858.​CD001419.
38.
Zurück zum Zitat Bramwell VH. Adjuvant chemotherapy for adult soft tissue sarcoma: is there a standard of care? J Clin Oncol. 2001;19(5):1235–7.PubMed Bramwell VH. Adjuvant chemotherapy for adult soft tissue sarcoma: is there a standard of care? J Clin Oncol. 2001;19(5):1235–7.PubMed
Metadaten
Titel
Prognostic factors that govern localized synovial sarcoma: a single institution retrospective study on 51 patients
verfasst von
Sameer Yaser
Samer Salah
Marwa Al-Shatti
Areej Abu-Sheikha
Ahmad Shehadeh
Iyad Sultan
Ahmad Salem
Maher Sughayer
Shaymaa Al-Loh
Abdelatif Al-Mousa
Publikationsdatum
01.06.2014
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 6/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0958-8

Weitere Artikel der Ausgabe 6/2014

Medical Oncology 6/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.